These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32612866)

  • 1. Current status and future directions of high-throughput ADME screening in drug discovery.
    Shou WZ
    J Pharm Anal; 2020 Jun; 10(3):201-208. PubMed ID: 32612866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in software tools for high-throughput in vitro ADME support with high-resolution MS.
    Paiva A; Shou WZ
    Bioanalysis; 2016 Aug; 8(16):1723-33. PubMed ID: 27487387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery.
    Komura H; Watanabe R; Mizuguchi K
    Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent development in software and automation tools for high-throughput discovery bioanalysis.
    Shou WZ; Zhang J
    Bioanalysis; 2012 May; 4(9):1097-109. PubMed ID: 22612689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of HT-ADME in drug discovery.
    Morgan D
    Bioanalysis; 2011 Nov; 3(21):2385-7. PubMed ID: 22074279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in predicting human ADME parameters in silico.
    Ekins S; Waller CL; Swaan PW; Cruciani G; Wrighton SA; Wikel JH
    J Pharmacol Toxicol Methods; 2000; 44(1):251-72. PubMed ID: 11274894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability.
    Gombar VK; Silver IS; Zhao Z
    Curr Top Med Chem; 2003; 3(11):1205-25. PubMed ID: 12769701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models.
    Hop CE; Cole MJ; Davidson RE; Duignan DB; Federico J; Janiszewski JS; Jenkins K; Krueger S; Lebowitz R; Liston TE; Mitchell W; Snyder M; Steyn SJ; Soglia JR; Taylor C; Troutman MD; Umland J; West M; Whalen KM; Zelesky V; Zhao SX
    Curr Drug Metab; 2008 Nov; 9(9):847-53. PubMed ID: 18991580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Present and future in vitro approaches for drug metabolism.
    Ekins S; Ring BJ; Grace J; McRobie-Belle DJ; Wrighton SA
    J Pharmacol Toxicol Methods; 2000; 44(1):313-24. PubMed ID: 11274898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools.
    Tao L; Zhang P; Qin C; Chen SY; Zhang C; Chen Z; Zhu F; Yang SY; Wei YQ; Chen YZ
    Adv Drug Deliv Rev; 2015 Jun; 86():83-100. PubMed ID: 26037068
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Ekins S; Lane TR; Urbina F; Puhl AC
    Xenobiotica; 2023 Aug; ():1-7. PubMed ID: 37539466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives.
    Bolleddula J; Brady K; Bruin G; Lee A; Martin JA; Walles M; Xu K; Yang TY; Zhu X; Yu H
    Drug Metab Dispos; 2022 Jun; 50(6):837-845. PubMed ID: 35149541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro ADME profiling using high-throughput rapidfire mass spectrometry: cytochrome p450 inhibition and metabolic stability assays.
    Wu X; Wang J; Tan L; Bui J; Gjerstad E; McMillan K; Zhang W
    J Biomol Screen; 2012 Jul; 17(6):761-72. PubMed ID: 22460176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery.
    Liu C
    Expert Opin Drug Discov; 2022 Jul; 17(7):775-787. PubMed ID: 35635049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.
    Lombardo F; Desai PV; Arimoto R; Desino KE; Fischer H; Keefer CE; Petersson C; Winiwarter S; Broccatelli F
    J Med Chem; 2017 Nov; 60(22):9097-9113. PubMed ID: 28609624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automation and robotics in ADME screening.
    Saunders KC
    Drug Discov Today Technol; 2004 Dec; 1(4):373-80. PubMed ID: 24981617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a rapid and integrated analysis system (RIAS) as a high-throughput processing tool for in vitro ADME samples by liquid chromatography/tandem mass spectrometry.
    Luippold AH; Arnhold T; Jörg W; Krüger B; Süssmuth RD
    J Biomol Screen; 2011 Mar; 16(3):370-7. PubMed ID: 21335598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantum Machine Learning Predicting ADME-Tox Properties in Drug Discovery.
    Bhatia AS; Saggi MK; Kais S
    J Chem Inf Model; 2023 Nov; 63(21):6476-6486. PubMed ID: 37603536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying machine learning techniques for ADME-Tox prediction: a review.
    Maltarollo VG; Gertrudes JC; Oliveira PR; Honorio KM
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):259-71. PubMed ID: 25440524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.